Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimacimab + semaglutide
- Development stage
- Unknown
- Lead developer
- Skye Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Nimacimab + semaglutide is an investigational combination therapy for obesity and overweight with weight-related comorbidities. Nimacimab is a first-in-class, peripherally-restricted monoclonal antibody that acts as a negative allosteric modulator (inverse agonist/antagonist) of the cannabinoid receptor type 1 (CB1). Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, already approved for type 2 diabetes and chronic weight management. The combination aims to leverage complementary mechanisms—CB1 inhibition by nimacimab to promote fat loss while preserving lean mass, and GLP-1 receptor activation by semaglutide to reduce appetite and improve glycemic control. Early clinical studies are evaluating the safety, tolerability, and efficacy of this combination in producing greater weight loss than either agent alone[2][4][5][7].
- Other names
- nimacimab + semaglutidenimacimab + Wegovy
02
Targets
CNR1 (Cannabinoid receptor 1)GLP1R (GLP-1R)
Beyond the preview
Go deeper on nimacimab + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimacimab + semaglutide.